Kristen Hege, MD, Oncology, San Francisco, CA, UCSF Medical Center

KristenM.HegeMD

Oncology San Francisco, CA

Hematologic Oncology

Physician

Are you Dr. Hege?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 36 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Kristen Hege, MD is an oncologist in San Francisco, California. She is currently licensed to practice medicine in California. She is affiliated with UCSF Medical Center and Zuckerberg San Francisco General Hospital and Trauma Center.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1989 - 1992
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - 2022

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Bristol Myers Squibb and Bluebird Bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-Cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20
    Bristol Myers Squibb and Bluebird Bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-Cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20May 13th, 2020
  • Bluebird Bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition
    Bluebird Bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and ExpositionDecember 9th, 2019
  • Bristol-Myers Squibb and Bluebird Bio Announce Positive Top-Line Results from the Pivotal Phase 2 KarMMa Study of Ide-Cel in Relapsed and Refractory Multiple Myeloma
    Bristol-Myers Squibb and Bluebird Bio Announce Positive Top-Line Results from the Pivotal Phase 2 KarMMa Study of Ide-Cel in Relapsed and Refractory Multiple MyelomaDecember 6th, 2019
  • Join now to see all

Hospital Affiliations